Background and motivation: While small molecules can be used in cancer diagnosis there is a need for imageable diagnostic NanoParticles (NPs) that act as surrogates for the therapeutic NPs. Many NPs are composed of hydrophobic materials so the challenge is to formulate hydrophobic imaging agents. To develop individualized medical treatments based on NP, a first step should be the selection of patients who are likely responders to the treatment as judged by imaging tumor accumulation of NPs. This requires NPs with the same size and structure as the subsequent therapeutic NPs but labelled with a long-lived radionuclide. Cobalt isotopes are good candidates for NP labelling since 55 Co has half-life of 17.5 h and positron energy of 570 keV while 57 Co (t 1/2 271.6 d) is an isotope suited for preclinical single photon emission tomography (SPECT) to visualize biodistribution and pharmacokinetics of NPs. We used the hydrophobic octaethyl porphyrin (OEP) to chelate cobalt and to encapsulate it inside hydrophobic liquid NPs (LNPs). We hypothesized that at least two additional hydrophobic axial ligands (oleylamine, OA) must be provided to the OEP-Co complex in order to encapsulate and retain Co inside LNP. Co-4OA complex, providing a half-life for retention in PBS of 170 h (7 days) while in the absence of the axial OA ligands was only 22 h. 5 Biodistribution Study: the in vivo biodistribution of LNP was studied in AR42J pancreatic tumor-bearing mice. The estimated half-life of LNPs in blood was about 7.2 h. Remarkably, the accumulation of LNPs in the tumor was as high as 9.4% ID/g 24 h after injection with a doubling time for tumor accumulation of 3.22 h. The most important result was that the nanoparticles could indeed accumulate in the AR42J tumors up to levels greater than those of other NPs previously measured in the same tumor model, and at about half the values reported for the molecular agent 57 Co-DOTATATE. Conclusions: The additional hydrophobic chelator OA was indeed needed to obtain a stable octahedral OEP-Co-4OA. Cobalt was actually well-retained inside LNP in the OEP-Co-4OA complex. The method described in the present work for the core-labelling of LNPs with cobalt is now ready for labeling of NPs with 55 Co, or indeed other hexadentate radionuclides of interest for preclinical in vivo PET-imaging and radio-therapeutics.
Introduction
In a series of preclinical anti-cancer studies we have recently shown in vitro that a new Niclosamide Stearate (NS) prodrug NanoParticle (NSNP) are taken up by breast and prostate cancer cells, and are very effective at reducing cell viability and inducing cancer cell kill [1] [2] . In vivo NSNP positively affects tumor growth delay in a breast cancer flank tumor [3] and metastatic spread in an osteosarcoma model of lung metastasis [3] . Interestingly, these studies have revealed new mechanisms of action for the "stealthy" prodrug nanoparticles. The new mechanisms are related to their kinetics of enzymolysis, their in vivo biodistribution and tumor-accumulation, as well as their route of intracellular uptake and transport. An essential part of understanding the mechanisms of action for this, (and indeed any), i.v.-injected anticancer nanoparticle is to have a clear and quantitative measure of the blood circulation half-life and rate and extent of its accumulation in the perivascular space of the tumor interstitium. The overall goal of this study was to design, develop, and test a new method to formulate hydrophobic Liquid Nano-Particles (LNP) so that they can contain the hydrophilic radio-diagnostic cobalt ion. The clinical requirement is that they are small enough (< 40 nm diameter, and preferably 20 nm -25 nm) such that they can potentially extravasate into the tumor interstitium of human tumors. Tested here in implanted AR42J pancreatic tumor-bearing mice, we explored the possibility that they can report on the vascular permeability and the potential Enhanced Permeability and Retention (EPR) effect for subsequent studies of similar-sized therapeutic NPs containing anti-cancer drugs [4] .
Clearly, EPR is a relative-size issue. Is the vasculature of each tumor permeable enough to allow each type of nanoparticle to extravasate? A recent comprehensive 10-year review by Wilhelm, et al. [5] , revealed that, on average, only 0.7% of the administered nanoparticle dose is found to be delivered to a solid tumor. Also, there is now an emerging recognition that the cut-off in NP size for passage through human tumor vasculature is probably much less than the value usually assumed from subcutaneous-implants in animal studies of 500 nm-1 μm [6] . Thus, it seems that some tumors are quite permeable, (especially implanted animal tumors used in preclinical studies), and so most nanoparticles can extravasate; while other tumors, perhaps especially in humans, are relatively impermeable, and so nanoparticles are excluded from the tumor interstitium and consequently have limited efficacy. For example, a trial by O'Brien in 2004 for metastatic breast cancer [7] showed that Doxil (Pegylated Liposomal Doxorubicin) was no better than free drug alone. That is, even though Doxorubicin has a half-life of only 2 min, and Doxil has a half-life of 73.9 h: "the overall survival (OS), was comparable with both treatments." "OS median Doxil, 21 months versus doxorubicin, 22 months). Doxil was tested [8] and later approved for ovarian cancer in 2005, but again, with little therapeutic benefit. When compared to topotecan, the time to progression for Doxil was 4.1 months; topotecan -4.2 months; overall median survival for Doxil was 14.4 months; topotecan 13.7 months; and the overall tumor response rates were 19.7% (47 patients) in the Doxil arm, and 17% (40 patients) in the topotecan arm. Compared to topotecan then, improvement in time-to-progression for Doxil was 0.1 months, which is only a 2.4% PFS. So why was Doxil so inefficient in these human cancers?
Tumor accumulation of Doxil has only been measured in 15 human patients by SPECT [9] and, in the 4 breast cancers studied the % injected dose that had accumulated in the tumors at 72 h was only 0.5% (5.3 ± 2.6% ID/kg) of that initially injected. So, while there still maybe problems associated with limited drug release, is Doxil, measured at 87.3 ± 8.5 nm diameter [10] , just too big to extravasate into ovarian and metastatic breast tumors in humans and provide the needed amount of drug to achieve efficacy?
In our opinion, it is this problem of making sure we all use wellcharacterized animal models in terms of their vascular permeability and nanoparticles capable of extravasating that is at the crux of whether nanomedicines will ever be successful. And these characteristics need to be established in the clinic with human cancer patients. It is this preclinical and clinical need that has motivated our efforts to provide a radioactive-ion-labelled hydrophobic nanoparticle capable of extravasating into the tumor interstitium and qualifying tumors as permeable or not, informing the "go, no-go" decisions for subsequent nanomedicine therapy.
Molecular diagnostics, theranostics, and diapeutics
While small molecules such as 18 F-Fluodeoxy glucose ( 18 F-FDG) [11, 12] and 11 C-acetate [13] can be effectively used in cancer diagnosis, they do not necessarily provide detailed information about uptake and accumulation of drugs formulated as NPs. Thus, there is a wellestablished need in the nanomedicine community for imageable diagnostic NPs that act as surrogates for the drug-nanoparticles. One approach is the theranostic nanoparticle. As reviewed by Xie et al. [14] and others [15, 16] the field of theranostics aims to "develop more specific, individualized therapies for various diseases, and to combine diagnostic and therapeutic capabilities into a single agent".
In this paper we focus on the idea that diagnostics needs to come first and actually inform therapeutic intervention. And so we are developing two agents that are expected to behave similarly when administered i.v., in terms of blood circulation and tumor accumulation in diagnosing and treating cancer. We therefore introduce the term, "Diapeutics" as a clinical-administration-sequence of 1) a diagnostic nanoparticle that will inform the clinician of the potential for nanomedicine intervention by 2) a subsequent nanoparticle containing the appropriate drug. As presented previously [4] , our bottom-up-and endogenous-inspired design for therapeutic NPs requires them to be of a similar material and similar size to the natural LDL. Thus, underlying this concept, specifically for cancer, is the recognition that rapidly growing cancer cells have high numbers of LDLRs [17] , some 4-100× greater than for normal cells. Numerous malignancies are known to over-express LDLR including brain, colon, prostate, adrenal, breast, lung, leukemia, sarcomas, and kidney tumors. As a result, cancers are known to take in more LDLs than normal cells, and in patients with cancer, their LDL count can even go down. An abundance of LDL receptor is also a prognostic indicator of metastatic potential, and the propensity to accumulate and store cholesteryl-ester is a sign of the aggressiveness of a patient's cancer [17] . Since LDLs are taken up by tumors [18] to aid their rapid cell-doubling and growth, the assumption is that, by definition, a size of 20-40 nm NP diameter is a critical parameter for promoting NP extravasation across the tumor vascular endothelium, such that, even without receptor-ligand targeting [4] the stealth NPs can then be taken up by the tumor cells in, at least, the perivascular space for therapeutic effects [3] .
Thus, like "theranostic nanomedicine" we take advantage of the high capacity of nanoparticles to perform both imaging and therapeutic functions, but prefer to separate the two functions into two ostensibly identical "diapeutic" nanoparticles. In the clinical situation then, the clinician needs to be informed if the nanoparticle cannot access the tumor interstitium, and if not, the therapeutic nanoparticle will be relatively useless in terms of tumor targeting. It is this concept then that has driven the research design for these studies. Further discussion of these ideas and their application in a specific "Individualized Medicine" example are given in Discussion.
The need for hydrophobic liquid NPs for PET imaging
Not surprisingly given the need for anticancer drugs to act intracellularly on often membrane-bound protein targets [19] , many of the drugs that are effective in cancer are relatively hydrophobic [20] . They are characterized as having high lipophilicity and low water-solubility and therefore low permeability (low absorption in humans) when taken orally [21] . They are classified in the Biopharmaceutics Classification System (BCS) [22] as BCS Class IV -Low Permeability, Low Solubility. In fact it is recognized that approximately 90% of pipeline drugs fall into the two low solubility categories of BCS II & IV [23] . This lack of good aqueous solubility is a key obstacle in the development and clinical use of these anticancer compounds including repurposed drugs (such as niclosamide) and newly developed smallmolecule anticancer compounds, where the use of a simple oral formulation often fails to elicit biological potency and/or provides sufficient exposure to even validate the drugs.
Consequently, in an attempt to solve this problem in the development of such highly notorious BCS class IV drugs [21] researchers have turned to more advanced formulations. Many of the NPs currently being tested and developed in nanomedicine for drug delivery are, by necessity, composed of hydrophobic-cored materials. In contract many of the imaging agents are ions, and so are very soluble in water and do not partition into low dielectric hydrophobic environments. The challenge then in making a diagnostic nanoparticle that matches the therapeutic nanoparticle is to formulate oil-soluble hydrophobic imaging agents.
In a recent paper [24] , we introduced a new approach to label the core of hydrophobic liquid NPs (LNPs) composed of glyceryl trioleate (triolein, TO) with water-soluble copper using the hydrophobic chelator octaethyl porphyrin (OEP). We demonstrated that a hydrophilic ion such as Cu 2+ could be well-encapsulated and retained within the low dielectric core of the LNP. The goal of this earlier study was to create such a particle with a diameter and surface structure similar to a subsequent therapeutic NP that would contain a hydrophobic drug. As outlined above, the eventual application of the developed LNP is in tumor diagnostics, requiring a particle that can measure the nanoparticle half-life in the blood stream and can take advantage of, and indeed demonstrate, the permeability of the tumor vasculature to NPs, indicating the likely tumor accumulation of subsequent anti-cancer NPs. When used as a non-invasive analysis of the body distribution of such nanocarriers, the NP is expected to be a useful tool for preclinical as well as clinical development of NPs and indeed new and existing nanomedicines.
While the encapsulation principle was demonstrated for copper ions by Hervella et al. [24] , there is a need to extend these approaches to other ions of interest that could bring NP diagnostics and therapeutics to the clinic. One limitation of OEP used as the chelator is that, due to the number of donor sites in the porphyrin ring (four), the coordination number of the final porphyrin-radionuclide complex is correspondingly only four. This coordination number is enough to chelate soft metals such as Cu [25] , but it is a limitation to stably chelate harder metals of interest, like, for example, 89 Zr, 86 Y, 57 Co, 58m
Co,or 55 Co [26] . The cobalt ion has a preferential coordination number of six and so has an octahedral geometry in metalloporphyrins [27] . It was therefore likely to not be as stably complexed by OEP and encapsulated in LNP as the fourcoordinated copper and a preferential square planar structure in metalloporphyrins [27] . In other porphyrin-cobalt systems, the demand of axial ligands has been supplied by the solvent [28] or, in the case of vitamin B12, by a cyanide and an adenosine group [29] , all of them with high water solubility. Since the OEP-Co complex is aimed to be encapsulated inside the hydrophobic core of the LNP, we hypothesized that not only do we have to use a hydrophobic chelator, such as OEP, we have also to provide additional hydrophobic axial ligands to the OEP-Co complex in order to encapsulate cobalt inside the LNP. To this end, oleylamine (OA) was selected due to its hydrophobic properties (log P: 7.9; S w : 0.15 μM) and to the well-known capacity of its amines to coordinate cobalt porphyrins [30] . We therefore expected that the stability of the six coordinated OEP-Co-OA complex would be better retained in LNPs compared with the four-coordinated OEP-Co. In this study then, we continued the work initiated with LNPs labelled with copper, but now including cobalt as the element that can be used to measure the biodistribution of the NP and actual concentrations of the LNP in tumors preclinically with either 57 Co and single photon emission tomography (SPECT) or 55 Co and positron emission tomography (PET).
Cobalt as a radionuclide of interest for molecule labeling
Isotopes of cobalt provide several interesting properties in diagnostics and radiotherapy. 55 Co is an isotope of interest for PET imaging with long-circulating molecules and macromolecules due to its long half-life (t ½ ) of 17.5 h and its average positron energy of 570 keV [31] . 57 Co (t 1/2 271.6 days, Eγ = 122 keV (86%), 136 keV (10%)), is a SPECT isotope that is useful for preclinical studies to visualize biodistribution and pharmacokinetics of NPs [32] and also for protocol optimizations as a longer-lived gamma-emitting surrogate to 55 Co [33, 34] . Co is an Auger-electron emitting isotope with potentially unique therapeutic applications [35, 36] . In the formulation studied here, we used 57 Co as the initial test ion and measured the ex-vivo biodistribution of LNPs.
Biodistribution studies based on cobalt have been reported for peptides [34] [35] [36] [37] [38] , including high contrast PET-imaging of gastrin releasing peptide receptor expression in prostate cancer using the cobaltlabelled bombesin antagonist RM26 [39] , affibodies [33, 40, 41] , vitamin B13 (Schiling test) [42] , lymphocytes [43] and even for therapeutic drugs (Bleomycin formulated inside liposomes [32] ). All these studies show the feasibility of using cobalt as an imaging agent for molecules with long half-lives in the bloodstream, suggesting that cobalt is a good candidate for the study of the biodistribution profile of NPs and their tumor accumulation.
NP labeling using long-lived radioisotopes
In preclinical studies, the in vivo imaging of NPs by PET has been carried out almost exclusively using 64 Cu as the contrast agent [44] [45] [46] [47] [48] [49] , hence, our initial interest in encapsulating copper [24] . In the abovereferenced 64 Cu studies, the particles were labelled by using a watersoluble chelator (usually DOTA) that is attached to the particle surface. While this method allowed the efficient labelling of the NPs surface, it showed in vivo instability due to trans-chelation reactions in the liver [50] [51] [52] [53] . In order to overcome this important drawback, we have therefore developed new techniques to label the core of LNPs [24] Cu-porphyrin phospholipid derivative [47] . Interestingly with respect to encapsulation and retention in the NP core, using the hydrophobic chelator OEP [24] we demonstrated that a hydrophilic ion such as Cu 2+ could be encapsulated and retained within the low dielectric core of a hydrophobic NP, but only if the core was a liquid (as TO) compared to a solid core (as cholesteryl acetate), hence our preference for Liquid cored Nanoparticles (LNP).
The aim of the current work was to label the core of similarly LNPs with the cobalt ion, recognizing that it requires hexadentate chelation. Surface-labeling is the most used strategy to label liposomes with radionuclides, since it can be done post NP formation by ligand attachment to preformed NPs. However, we now present a new example of the radionuclide-labeling for our NP achieved inside the core of the hydrophobic LNP. We modified the core-loading method used for copper ions [24] to successfully label NPs with cobalt ions by including OA. This new method is now available alternative to surface chelators for labeling hydrophobic NPs for in vivo imaging, and we show here the principles underlying their encapsulation-stability and preclinical-utility.
Materials and methods

Materials
TO, OEP (2, 3, 7, 8, 12, 13, 17, 18 -Octaethyl 21H,23H-porphyrin), OA, and cobalt (II) chloride were purchased from Sigma-Aldrich. Carrierfree Co-57 (0.1 M HCl, 370 MBq) was purchased from Perkin-Elmer. Cholesterol, 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC), and 1,2-distearoyl-sn-glycero-3-phosphor-ethanolamine-N-[amino(polyethyleneglycol)-2000] (DSPE-PEG 2000 ) were purchased from Avanti
Lipids. Ethanol (99%) and chloroform were purchased from VWR. Human serum from human male AB plasma, sterile filtered, was purchased from Sigma. Other chemicals were purchased from SigmaAldrich. All reagents and solvents were used without further purification.
Safety/Toxicity
The chemical composition of the LNP was selected following the natural design of the endogenous LDL, and so the LNP are composed by phospholipids, cholesterol and triolein, materials that are widely used in drug delivery due to the lack of toxicity. These materials are Generally Regarded as Safe (GRAS) as reviewed by van Hoogevest and Wendel [55] . While Porphyrin-based compounds like OEP, can generate reactive singlet oxygen when activated by light, in the absence of light the porphyrin has very low toxicity, with an IC50 of 100 μM [56, 57] . Finally, for Cobalt isotopes, Jansen et al. [58] concluded that a safe dose for free 57 Co in humans would be 14.8 MBq. In this first preclinical study our injected dose was 62 ± 4 kBq per animal that was shown to be safe in terms of animal weights. Thus, it appears to be safely encapsulated in the nanoparticles, and so the human dose, if trialed, may actually be used at a higher dose than for free cobalt. (25 nmol) were dissolved in 1 mL of ethanol in a sealed glass vial, and the solution was placed in a microwave oven for 3 min at 850 W to produce the OEP-Co complex. After the solution was cooled down to room temperature, OA (100 nmol i.e., a mol ratio of 4:1 with OEP-Co, unless otherwise specified) was added to the solution and the resulting mixture was placed again in the microwave oven for another 1 min at 850 W (Scheme 1).The resulting OEP-Co-OA complex was then used without further purification.
The chelation reaction was monitored by UV-Vis spectroscopy by following the spectral changes of OEP in the presence of different amounts of CoCl 2 . The association constant was calculated by measuring the decrease in absorbance of OEP (5 nmol) in presence of different amounts of CoCl 2 (ranging from 0 to 5 μM). The mixture was heated in a microwave for 3 min at 850 W and the UV-Vis spectra were recorded in a Shimadzu UV-2600 spectrophotometer. All measurements were carried out in triplicate at 20°C.
The chelation efficacy of 57 Co was evaluated by instant thin layer chromatography (TLC) using chromatography strips (Biodex), mounted with the 5 μL sample and eluted with 0.2 M citric acid (pH 2) and cut at the line. The radioactivity of both halves was measured in an Atomlab 950 well counter calibrated with Cs-137. Free cobalt eluted on top while OEP- 57 Co-OA was retained at the bottom.
NP formulation and Characterization
Once cobalt was chelated by OEP or OEP plus OA, the complex was encapsulated inside LNP using the fast ethanol injection method, again developed previously for encapsulation of OEP-Cu [24] . Based on our previous studies [4, 24, 59] we selected TO as a model hydrophobic molecule, and solvent for the OEP-Co-OA complex, because of its high insolubility in water, and as a test particle that could be replaced in subsequent studies by hydrophobic drugs to create a potentially therapeutic LNP. Moreover, having already found that OEP was better retained in a liquid-than a solid-core [24, 59] efforts were made to create the smallest NP with this material and its encapsulated complexes. The components of the LNP and their physicochemical properties are listed in Table 1 .
NPs were prepared using a modification of the solvent injection technique, named fast ethanol injection [24] . Briefly, all the components that form the NPs, TO (1 μmol), DSPC (0.45 μmol), cholesterol (0.5 μmol) and DSPE-PEG 2000 (0.05 μmol) and the Co complexes, OEPCo or OEP-Co-OA (both at 25 nmol), were first dissolved in 1 mL ethanol. NPs were then made by using an automated syringe (eVOL XCHANGE, SGE analytical sciences) to inject the resulting 1 mL ethanol solution at a flow rate of 833 μL/s directly into 9 mL of deionized water, held in a 12 mL scintillation vial. Upon completion of mixing, the ethanol was removed by ultrafiltration (Amicon tubes, size cut-off 100.000 Da, 4000 rcf, 10 min). The sample was washed with deionized water 2 times, and again re-concentrated by removing the water by ultrafiltration. The final volume was adjusted to 10 mL to give a final particle suspension concentration of cobalt of 2.5 μM, and the particles were then used without further purification. were recorded in a Shimadzu UV-2600 spectrophotometer. All measurements were carried out in triplicates at 20°C.
Encapsulation efficiency of OEP-Co-OA in LNP 2.2.3.1. Encapsulation efficiency of OEP-Co-OA in LNP.
The encapsulation efficiency of OEP-Co-OA by NPs was first evaluated by fluorescence spectroscopy. This assay is based on the fluorescence of OEP-Co-OA that is only observed when the molecule is solubilized inside LNP, while it is totally quenched when dispersed in water. Encapsulation efficiency of OEP-Co-OA to NPs was measured by monitoring the fluorescent signal of LNP (200 μM) with increasing concentrations of OEP-Co-OA (0-10 mol%). The fluorescence spectra were recorded in an ISS Chronos Lifetime Spectrofluorometer, using an excitation wavelength of 400 nm. The emission was scanned over the range of 550-750 nm. Both the excitation and the emission slit widths were 1 nm. All measurements were carried out in triplicates at 20°C.
Encapsulation efficiency of OEP-57
Co-OA in LNP. For the radioactive ion, 57 Co, the encapsulation efficiency of chelated 57 Co-OA and the encapsulation efficiency was measured by TLC using chromatography strips (Biodex), mounted with 5 μL sample and eluted with 0.2 M citric acid (pH 2) and cut at the line. The radioactivity of both halves was measured in an Atomlab 950 well counter calibrated with Cs-137.The free 57 Co eluted to the top of the TLC strip while OEP- 57 Co and OEP- 57 Co-OA were retained in the NP and did not elute and so was measured at the bottom of the TLC strip as described above. All measurements were carried out in triplicate.
OEP-Co or OEP-Co-OA Retention and stability studies at 37°C
NP stability against aggregation and the retention of the radioisotope 57 Co inside LNP were clearly key requirements for successful in vivo studies. The LNP were designed and intended for subsequently delivery of 57 Co (or 55 Co) to the perivascular space of tumors. As mentioned above, it was recognized that there is likely to be an upper limit to the extravasation from blood circulation into the tumor interstitium by the EPR effect, and so it was necessary to check, as much as possible in vitro, that particle size remained unaltered in the presence of ionic media (PBS). Thus, the stability of OEP-Co-OA loaded NPs against any size change versus time was evaluated in PBS. Any loss of 57 Co was also evaluated in PBS as well as serum in order to ensure that the 57 Co loading was stably retained inside the LNP in these media.
Size stability in PBS.
LNP loaded with OEP-Co or OEP-Co-OA were dispersed in PBS to a final LNP concentration of 200 μM (OEP-Co or OEP-Co-OA concentration was 2.5 μM). The samples were then placed at 37°C and the particle size was measured versus time during 24 h. The size of NPs and P.I. were measured by DLS in a Beckman Coulter DelsaMax Pro (laser power: 50 mW, wavelength: 532 nm). All measurements were carried out in triplicate. Co-OA were also incubated in human plasma at 37°C for 24 h. The encapsulation efficiency of the samples versus time was measured by TLC as described above (see section, 3.2 Encapsulation efficiency of OEP- 57 Co-OA in LNP).
OEP-
All measurements were carried out in triplicate.
In vivo biodistribution study
The biodistribution studies for this LNP were designed to obtain a quantitative measure of the biodistribution profile and the pharmacokinetics of the nanoparticles. Principally, this study was to show if and to what extent the LNP were accumulated in tumors in order to pave the way for formulation design and testing of a subsequent therapeutic NPs. Following i.v. injection into AR42J tumor-bearing mice of the OEP-Co-OA loaded LNP, measurements included circulation half-life of the intact LNP in the blood stream and its accumulation in these implanted pancreatic tumors. Other important pharmacokinetic parameters assessed included any potential for accumulation by organs and tissues (kidneys, adrenals, stomach, small intestine, pancreas, lungs, heart), and especially those of the RES, the liver and the spleen.
OEP- 57 Co-OA NPs were prepared for the ex vivo biodistribution study as described above (2. NP formulation) using a radioactivity of 64.8 MBq of 57 CoCl 2 (~1.6 nmol) chelated with 25 nmol of OEP and 100 nmol of OA in 1 μmol of TO and1 μmol of phospholipids. After fabrication, the particles were suspended in PBS and filtered with a 0.45 μm sterile filter before injection via tail vein. Injections into the animals were made by diluting the stock suspension of LNP with PBS. 
Results
Following the work on copper ions encapsulated inside the core of hydrophobic LNP [24] , we now present the results of a comprehensive study of the steps of optimization that were carried out for cobalt to: 1. Chelate the cobalt; 2. Formulate the LNP; 3. Encapsulate chelated Co 2+ ions in the LNP core; 4. Measure how well the cobalt was retained in the NPs; and 5. Measure the NP biodistribution in vivo, including tumor accumulation in tumor-bearing mice. Note: we used non-radioactive 59 Co for developing all the chelation, encapsulation, and retention studies, and switched to 57 Co for the in vivo biodistribution and tumor accumulation studies. The lipids used to prepare Liquid NPs (LNP) were Triolein (TO), DSPC, Cholesterol and DSPEPEG. Octaethylporphyrin (OEP) and cobalt were encapsulated in this core. Oleyl Amine (OA) was used as a co-ligand. All water solubility and LogPs were obtained from ALOGPS (vclab.org).
Cobalt chelation
Cobalt chelation by OEP
Non-radioactive 59 Co was first chelated by the hydrophobic OEP to test its suitability for encapsulation into the hydrophobic LNP.
Association constant of Co to OEP.
The association constant of cobalt to OEP was measured by recording the UV-Vis spectra of OEP (25 μM) after chelation with different amounts of CoCl 2 . As can be seen in Fig. 1A , the absorbance of the Søret band of OEP (395 nm) decreased when OEP was chelated with different concentrations of CoCl 2 ranging from 0 to 50 μM. In tandem, a new peak at 411 nm increased in absorbance with increasing concentrations of cobalt. This new peak is attributed to the formation of the OEP-Co complex; its absorbance reached a maximum at the expected 1:1 mol ratio of OEP and cobalt, i.e., at 25 μM CoCl 2 and 25 μM OEP (dotted line in Fig. 1A ). The decrease in the Søret band of OEP (395 nm) with increasing concentration of cobalt was then used to measure the association constant of Co to OEP following a Benesi-Hildebrand plot [60] . Fig. 1B shows the fit of the experimental data to the BenesiHildebrand plot defined by Eq. (1): 
OEP-Co coordination by OA
We evaluated the number of moles of the hydrophobic ligand OA required to chelate the OEP-Co. The change in the coordination number of Co inside OEP-Co from 4 to 6, using OA as the axial ligand of OEP-Co, was monitored by UV-Vis spectra. While it was expected that the molecular-equivalent would be 2 per OEP-Co, we explored increasing amounts of OA in the coordination reaction with OEP-Co ranging from 12.5 μM (0.5 equivalents of OA in relation to OEP-Co) to 400 μM (16 equivalents of OA in relation to OEP-Co). The results are shown in Fig. 2 .
Since cobalt was chelated with OEP in ethanol, initially we tested the effect of OA on the OEP-Co coordination in this solvent ( Fig. 2A) . However, ethanol itself adds two axial ligands to the planar structure of OEP-Co [61] , thereby interfering with the OA donation. Thus, in ethanol, the UV-Vis spectra of OEP-Co in the absence of OA had a Søret band centered at 411 nm that was only slightly red-shifted to 413 nm in the presence of 1 equivalent of OA (25 μM). Coordination with higher amounts of OA did not result in any change in the UV-Vis spectra, even at high OA concentrations of 400 μM (16 equivalents of OA).
Obviously, ethanol is not a stable ligand in the LNP (it would rapidly dissolve out of the LNP when introduced into aqueous media), and so we had to choose a different solvent to measure the OA chelation. This solvent was chloroform that has a much lower donor number than ethanol (4 kcal mol −1 vs ethanol, which is 19.2 kcal mol −1 ). Thus, a different and preferable behavior was observed when the complexes were dissolved in chloroform (Fig. 2B ). An intense blue-shift was observed for formation of the OEP-Co complex with this change in solvent, from 411 nm in ethanol to 393 nm in chloroform (the black lines in Fig. 2A and B respectively). No further blue-shift was observed for the OEP-Co-OA complex prepared with 2 or more equivalents of OA, and the Søret band of OEP (originally at 395 nm) was now measured at 414 nm. With this improved, less-interacting, solvent of chloroform, the addition of 0.5 and 1 equivalents of OA, gave two peaks that were observed in the UV-Vis spectra at 392 nm and 414 nm, indicating the co-existence of OEP-Co and OEP-Co-OA. In order to optimize the amount of OA needed to fully chelate Co in the OEP-Co-OA complex, increasing amounts of OA equivalents were added and a plot of the absorbance at 392 nm (corresponding to the OEP-Co complex) and the absorbance at 414 nm (corresponding to OEP-Co-OA) vs the equivalents of OA was made. It can be seen from Fig. 2C , that a minimum value for the absorbance at 392 nm and a maximum value for the absorbance at 414 nm were obtained at a concentration of OA of 4 equivalents (100 μM). Therefore the molar ratio 1:4 (for OEP-Co:OA) was selected for the next studies, hence now designated with the term OEP-Co-4OA.
Formulation and characterization of LNP
LNP formulation including the presence of OEP-Co-4OA
3.2.1.1. Influence of OA equivalents on size of LNP. All LNP were formulated using the same fast solvent injection method described in our previous paper [24] . Blank LNP, composed by TO (1 μmol), DSPC (0.45 μmol), cholesterol (0.5 μmol) and DSPE-PEG 2000 (0.05 μmol), were prepared by this method. The diameter measured after the solvent injection was 28 ± 4 nm, with a P.I. of 0.27. This value is the cumulative average of the sample. The mass-weighted average was calculated from the ratio between the intercept and the slope of the linear fit. All measurements were recorded in triplicate in ethanol at 20°C.
shows a mean value of 22 ± 4 nm, while the number-weighted average was 20 ± 3 nm. After the sample was concentrated, each of the samples was dispersed in PBS and the diameter was measured again. The cumulative average diameters measured for each of the LNP was as follows: for blank LNP in PBS, the diameters were 33 ± 4 nm with a P.I. of 0.17; LNP labelled with 2.5 mol% of OEP-Co in PBS were 32 ± 3 nm, the same as blank LNP; LNP labelled with 2.5 mol% of OEP-Co plus the OA were also 32 ± 3 nm for 1 eq of OA, but the diameter increased to 37.5 nm ± 3 nm for 2 eq of OA, and to 40 ± 5 nm for 4 and 8 equivalents of OA.
Thus, as shown in Fig. 3 , in contrast to the unlabeled and OEP-Co labelled LNP, coordination of OEP-Co with different amounts of OA (of 2, 3, 4 and 8 equivalents) resulted in a slight but significant increase (p < 0.05) in the particle diameter especially with 4 and 8 equivalents of OA.
All the above data is given in terms of the cumulative average size. Since we are attempting to make LDL-sized NPs (~20 nm diameter [62] ) for purposes of maximizing eventual in vivo EPR, it is important to understand the results in terms of what the DLS provides. The particle sizes measured by DLS were dependent on the mode employed for measurements. Thus, for completion, for each measurement mode, the average size of the sample prepared for the final injectable formulation of LNP, labelled with 2.5 mol% of OEP-Co plus 4 equivalents of OA, is shown in Supplemental Information Fig. S1 . Its intensity-weighted diameter was 51 ± 5 nm, whereas the mass-weighted diameter was measured to be 40 ± 5 nm, and the number-weighted diameter was 34 ± 5 nm. Note, these diameters also include the PEG layer extending 3.5 nm from the lipid head-groups [63] , and so the core plus lipid monolayer would be diameter minus 7 nm. See later in Discussion, Scheme 2.
Regarding surface charge of the LNP, the results (also in Fig. 3 ) showed that the Z-potential of LNP loaded with OEP-Co-OA was not dependent on the concentration of OA and a Z-potential value around −5.2 ± 3 mV as measured for all NPs dispersed in PBS indicating that the OA was not surface active but bound inside the TO core as a cooperative ligand to the OEP-Co complexes as intended.
Establishing the required equivalents of OA for encapsulation of OEP-Co in NPs.
Here, we first established the required equivalents of OA for encapsulation of OEP-Co in LNP at a single 2.5 μM concentration of OEP-Co and then varied the OA. The formulation of OEP-Co-OA prepared with different equivalent amounts of OA in OEP-Co loaded LNP was studied by UV-Vis spectroscopy. The results in Fig. 4A show the differences in the UV-Vis spectra of LNP loaded with OEP-Co and OEP-Co-OA. As expected from the hydrophobic nature of the LNP core, it can be seen that the spectra of OEP-Co in LNP is similar to the spectra recorded in chloroform (Fig. 2B) . That is, in Fig. 4A , in the absence of OA (i.e. just OEP-Co), the Søret band (black line) was centered at 392 nm while in the presence of OA (i.e. OEP-Co-OA) the Søret band (grey line) was centered at 414 nm. Interestingly, it should be noted that, for OEP-Co-OA loaded LNP prepared with 0.5 and 1 equivalents of OA, the Søret band was divided into two bands, suggesting the presence of both OEP-Co and OEP-Co-OA complexes.
The full conversion from OEP-Co to OEP-Co-OA is represented in Fig. 4B , where the absorbance at 414 nm (maximum for OEP-Co-OA complexes) and the absorbance at 393 nm (maximum for OEP-Co complexes) are plotted vs the equivalents of OA. It can be seen that a maximum value for the absorbance at 414 nm is observed after 2 equivalents of OA. These results were in good agreement with the spectroscopic study carried out for the OEP-Co complex dissolved in chloroform (Fig. 2C) , where saturation was complete at 4 equivalents of OA. As we have shown previously [59] , TO and chloroform are very close in terms of solvency for OEP complexes, i.e., the solubility limit of OEP in pure chloroform was 10 mM, and its solubility limit in pure TO was found to be very similar at 9.6 mM. However, since they are not exactly identical solvents, to be safe and sure, the OEP-Co-OA complex was encapsulated in LNP with 4 equivalents of OA. Thus, while only 2 equivalents would seem to be required to occupy the additional two valence of the octahedral coordination geometry of Co, and this spectrophotometric study confirmed this 1:2 coordination of OEP-Co with OA, we actually used 4 equivalents of OA of in the OEP-Co-OA complex for in vivo testing, and so prepared it with the molar ratios of 1:1:4.
Influence of OEP-Co-4OA-loading on LNP size and maximum encapsulation of OEP-Co-4OA inside LNP
Having established the 1:1:4 coordination for OEP-Co-4OA at one loading-concentration (2.5 μM OEP-Co-4OA in 100 μM TO), we then evaluated the influence of the OEP-Co-4OA loading on the obtained diameter of the OEP-Co-4OA loaded LNP.
Influence of OEP-Co-4OA
loading on LNP size. LNP were formulated with different amounts of OEP-Co-4OA, ranging from 0 to 10 mol% (0-10 μM) with respect to TO (100 μM). The results are shown in Fig. 5 . The average size of blank LNP in PBS was 32 ± 3 nm. The size increased with increasing concentration of OEP-Co-4OA, until a diameter of 40 ± 5 nm was measured for LNP with an OEP-Co-4OA loading above 1.5 mol%. As we have shown previously, OEP can also form crystalline material that could exist as their own NPs if not encapsulated [59] . Thus, as a control, the free OEP-Co-4OA complex in the absence of LNP was also formulated using the same solvent injection method. The average diameter of pure free OEP-Co-4OA NPs dispersed in PBS was 77 ± 11 nm.
Thus, the results obtained from the size measurements suggested that LNP showed a slight increase in average size when labelled with OEP-Co-4OA up to 2 and 4 mol% and that their size actually did not increase beyond that point.
Maximum Encapsulation of OEP-Co-4OA in LNP.
We also determined the maximum amount of OEP-Co-4OA at this optimal ratio 1:1:4 that could be encapsulated in the LNP. The encapsulation of OEP-Co-4OA in LNP was evaluated by UV-Vis and fluorescent spectroscopy. The UV-Vis spectra of OEP-Co-4OA were recorded for LNP loaded with different amounts of OEP-Co-4OA, from 0 to 10 mol% ( Fig. 6A) . We did not observe any change in the position of the Søret band that was measured at 414 nm independent of the concentration of OEP-Co-4OA in the LNP. Also, the shape of the Søret band did not change with the concentration of OEP-Co-4OA, and it was the same as that for OEP-Co-4OA suspension in water (Fig. 6A, insert) .
In order to calculate the total concentration of OEP-Co-4OA in the LNP suspension a linear calibration plot was made of the absorbance at 414 nm (maximum for the Søret band of OEP-Co-4OA in hydrophobic environments) vs the concentration of OEP-Co-4OA (Fig. 6B , open circles, left hand axis).
The encapsulation efficiency was then evaluated by fluorescence spectroscopy (Fig. 6B) . The fluorescent signal of OEP-Co-4OA dispersed in water was fully quenched giving no measureable fluorescent intensity for OEP-Co-4OA prepared in the absence of LNP. On the other hand, when OEP-Co-4OA was encapsulated in LNP, the fluorescent signal was recovered and the particles became fluorescent. This fact allowed for the quantification of the encapsulation of OEP-Co-4OA in LNP without using any separation technique. The fluorescent intensity was measured for OEP-Co-4OA in the range of 0-100 μM for LNP (100 μM), i.e., up to a 1:1 mol ratio. The results show that the fluorescence intensity gradually increased with increasing concentration of OEP-Co-4OA until a plateau was reached at 5 mol% concentration, which therefore represents the maximum loading capacity of OEP-Co-4OA in LNP as 5 mol%. 57 
Retention of radioactive OEP-
Co-OA complex in the LNPs and stability over time against aggregation in PBS
While all of the chelation, loading, and characterization studies were carried out with non-radioactive 59 Co, the actual formulation to be used in vivo had to be tested as the radioactive 57 Co in the OEP-Co-4OA loaded LNPs, and compared again to OEP- 57 Co chelated cobalt without the four additional OA ligands. 57 Co-4OA retention in PBS and serum at 37°C. Co-4OA complex providing a half-life for retention in PBS of 170 h (7 days). In the absence of the axial OA ligands, the half-life for retention of 57 Co was only 22 h, such that the amount of free 57 Co after 24 h incubation at 37°C was measured to be 62%, which was significantly higher than the amount of free 57 Co measured for OEP- 57 Co-4OA, which was only 12%. The retention of 57 Co inside LNP labelled with OEP- 57 Co-4OA was also tested in human serum (open squares). The retention followed the retention seen in PBS. Importantly, after 24 h incubation at 37°C, 89% of the initial amount of 57 Co was retained inside the LNP. As shown later, in Fig. 9 , this retention was found to be actually much longer than the LNP circulation half-life in the blood stream and so provided enough stability for the in vivo studies.
OEP-
Size stability of LNP loaded with OEP-Co and OEP-Co-4OA in ionic buffer (PBS).
The size-evolution of LNP loaded with OEP-Co and OEP-Co-4OA was also measured upon incubation in PBS at 37°C (Fig. 7B) . The initial particle average diameter for OEP-Co loaded LNP was 34 ± 5 nm and for OEP-Co-4OA LNP was 38 ± 6 nm. The particle size did not change significantly during the first 4 h of incubation in PBS. However, after 24 h there was a small but significant (p < .05) increase of 3 nm for both OEP-Co and OEP-Co-4OA loaded LNP, to 37 nm and 41 nm respectively. Based on these loading-, retention-and size-stability results, the complex OEP- 57 Co-4OA was selected for labelling LNP and then used for the biodistribution study, as presented next.
Biodistribution study of LNP loaded with OEP-57
Co-4OA in tumor-bearing mice Finally, the in vivo biodistribution of LNP was studied in AR42J pancreatic tumor-bearing mice. To reiterate, after all the processing, the eventual average particle size of the injected LNP in PBS was 40 ± 5 nm and the encapsulation efficiency of OEP- Co-4OA amongst all LNPs, was 33 57 Co atoms per LNP. The LNP biodistribution was measured 1 h, 4 h and 24 h after tail vein injection. Results are shown in Fig. 8 .
The concentration of LNP particles in the blood 1 h after injection was 33% ID/g, then it was decreased to 26% ID/g after 4 h and then to 4%ID/g at 24 h. As for accumulation in the various organs there was immediate uptake by the kidneys (5%ID/g), adrenals (5%ID/g), pancreas (2% ID/g), lungs (9% ID/g) and heart (6% ID/g) at 1 h, and over the 24 h they each showed decreases in LNP content. There was a relatively small build up on the order of 2-4%ID/g in other minor organs, stomach, small intestine and colon. The main organs that showed an initial major uptake were the liver and spleen. The initial liver uptake measured 1 h after injection was 9% ID/g, and increased to 23% ID/g 24 h after injection. Uptake in the spleen was also high, with 20% ID/g measured after 24 h. The most important data was that, as shown in Fig. 8 , the tumor uptake was 3%ID/g 1 h after particle injection and increased over time, with a particle concentration of 6 and 9%ID/g at 4 and 24 h after injection, respectively.
Discussion
The most important result from this study was that a new method has been successfully designed and tested to formulate hydrophobic LNP so that they can contain the hydrophilic radio-diagnostic cobalt ion and are small enough (40 nm diameter) such that they can extravasate into the tumor interstitium of implanted AR42J pancreatic tumor-bearing mice. They can therefore report on the vascular permeability and the potential EPR effect for subsequent similar sized therapeutic NPs containing an anti-cancer drug [4] . Chelation of the cobalt ion was achieved by using a hydrophobic porphyrin (OEP) and four additional hydrophobic ligands (OA) at concentrations of 5 mol% with respect to the host LNP core composed of TO. Since cobalt has a preferential coordination number of six [27] , by chelating it in the hydrophobic OEP and adding excess (4 equivalents) of the similarly hydrophobic OA, its octahedral geometry was stably satisfied and the cobalt was well-encapsulated and retained in the LNP. When 57 Co was used in this formulation, the LNP were shown to remain in blood circulation with a t 1/2 of 7.2 h. Importantly, the LNP accumulated in the implanted tumors to levels of 9.4%ID/g with a half time for accumulation of about 2 h. The final 40 nm average diameter LNP containing one of several radioactive cobalt isotopes is now ready for protocol optimization and preclinical studies for cobalt based imaging and therapy. For example this could include the long-lived 57 Co for preclinical SPECT imaging, or the positron emitting radionuclide 55 Co, or indeed 58m
Co, the Auger-electron emitting isotope with potential therapeutic applications [35, 36] .
What follows next are discussions of the practical challenges solved and the significance of the data in each of the five specific aims of the project: 1. Chelate, 2. Formulate, 3. Encapsulate, 4. Retain, and 5. Measured in vivo biodistribution of LNP labelled with 57 Co in a mouse tumor model.
Chelation of cobalt by Octaethyl Porphyrin
The value for the association constant measured in Fig. 1B was in the same range as the association constant we had measured earlier for OEP-Cu (5.44 × 10 5 M −1 ) [24] . This result is in agreement with the dissociation kinetics of the same complexes from porphyrins, measured albeit under acidic conditions [64] . Regarding the amount of OA required, while only 2 OAs are actually required for satisfying the additional empty chelate sites for the hexadentate Co, full chelation efficiency in the LNPs was best obtained when 4 equivalents of OA were added to OEP-Co, i.e., 2 in excess. The efficiency of the axial coordination of amines to metalloporphyrins is higher for amines with low pKb [30] , which is the case for OA (pKb of 3.3). Thus, the hexacoordinate OEP-Co could not be achieved using only OEP as chelator due to the planar symmetry of OEP, and an excess of OEP did not provide the additional axial ligands needed to get the coordination numbers higher than 4. Therefore, the hydrophobic ligand OA was used to complete the coordination sphere and to coordinate OEP-Co in the axial position (Scheme 1) since it is a hydrophobic molecule that can be retained inside LNP (log P 7.9; S w 0.15 μM).
Formulation and characterization of LNP with OEP-Co-OA
The two most important physical parameters to measure that characterize LNP for in vitro and in vivo use were the particle diameter and the surface charge expressed as the zeta potential.
Particle size
As introduced above, a particle diameter of 20 nm -25 nm is a key determinant of any NP's ability to extravasate into the tumor interstitium (as would an LDL). It was therefore our specific aim to formulate imageable LNP with diameters at or below 40 nm and preferably on the order of 20 nm to match the size of natural LDLs and to also avoid any aggregation in vitro or compromised circulation in vivo due to protein-binding. The lipid monolayer, comprised the well-recognized stealthy composition containing 5 mol% PEG lipids (DSPE-PEG 2000 ) and was selected in order to provide for long circulation by decreasing in vivo uptake by the reticulo-endothelial system (RES) [65] , i.e., mainly the liver and spleen [66, 67] . It is well know that extended circulation half-life of liposomes can also be increased by a very mechanically strong [68] and relatively impermeable [69, 70] monolayer containing cholesterol packed into the monolayer with saturated acyl chain lipids. Thus, we chose the host monolayer (that encapsulated the TO core) to be composed of DSPC:Cholesterol at a 1:1 mol ratio [65, 68] , that gave the final formulation of DSPC:Cholesterol:DSPE-PEG 2000 45:50:5. The size measurements showed 34 ± 5 nm for the numberweighted average of the final formulation used in the in vivo tests. Studies by Walke [71] have shown that Triolein naturally precipitates out from ethanol during a rapid solvent exchange to give a size (20 nm diameter nanoparticles) that is predicted by classic nucleation theory (see review by Karthika, [72] . When lipids such as palmitoyl-oleylphosphatidylcholine or the same DSPC-Chol-DSPE-PEG 2000 as used here, were included, this 20 nm-sized nucleate was kinetically trapped by the lipid monolayer and did not grow by aggregation, coalescence or ripening [71] . Thus, our initial optimizations for the conditions that are required to make extravasate-able LNP came very close to this minimum size.
Zeta potential
Similarly for the zeta potential, there was actually no change in this parameter for LNP loaded with OEP-Co coordinated with different concentrations of OA (0-8 equivalents) . The Z potential of LNP loaded with OEP-Co-OA was measured to be −5 mV independent of the concentration of OA (Fig. 3) . This was despite the fact that at pH 7.4 any of the OA located on the particles surface would be protonated and therefore positively charged. A negative Z potential has routinely been measured for ostensibly neutral DSPC:Cholesterol liposomes. This apparent anomaly was recently attributed to a decrease in Na + binding [73] , leading to a similar value (−5 mV) for lipid cholesterol bilayer liposomes as in our LNP. In other work, in DSPC-coated nano-emulsions [74] , it was shown that the addition of 2.5 mol% OA (compared to the phospholipid) resulted in only a very slight increase in the Z potential to positive values of just +0.13 mV averaged for DSPC, DPPC and two oils, castor oil and isopropyl myristate. Our results showed the slight negative Z potentials of −5 mV for the lipid-coated particles and in the presence of excess OA. The plane of shear at which the zeta potential is measured can be as much as tens to hundreds of nm away from the surface for 5 nm and 15 nm NPs [75] , Thus, in our case, for similarly small 30 -40 nm LNPs, it is likely that zeta potential, as an actual measurement, is less meaningful for these small nanoparticles than for larger microparticles where such measurements are used to understand the balance between van der Waals and electrostatics that are known to create force-and energy-potential balances that, in turn, stabilize or allow flocculation. In any event, for our nano-particles the most important repulsive stabilizing potential was that of the steric barrier provided by the PEG 2000 .
Encapsulation of OEP-Co-OA inside LNP
As demonstrated here, in order to encapsulate the very hydrophilic ion Co 2+ (logP = −0.57) we tested whether the octahedral OEP-Co-OA can be used to label LNP. The solubility of cobalt in water as CoCl 2 S w = 4 M, based on theoretical calculations using the ALOGP method [76] (Table 1) , is reduced 2 × 10 7 fold to 0.2 μM when the ion is chelated and forms the OEP-Co-OA complex. This is expected since, as designed, the two chelators used to coordinate Co 2+ , OEP and OA, are both very hydrophobic (OEP logP = 7.8, OA logP = 7.5), with water solubilities of S w = 16 μM, and S w = 0.15 μM, respectively. Taking into account that the core of LNP is composed of TO (logP =10.8; S w = 7 nM), it is expected that OEP-Co-4OA was located within the hydrophobic core of the LNP and therefore could, in principle, affect the NP size. The effect of the OEP-Co-4OA on the particle size of the final composition of the NPs was first evaluated, followed by the quantification of the encapsulation efficiency.
Effect of encapsulating OEP-Co-4OA on NP size
As with the earlier results on OEP encapsulation (2.1 Particle size), the encapsulation of now OEP-Co-4OA had only a small influence over the original particle size (of 32 ± 3 nm) of LNP. As shown in Fig. 5 , at low OEP-Co-4OA concentrations (lower than 1.5 mol%) the diameter was increased only slightly and not significantly to 33 nm (p < 0.05), while at concentrations higher than 1.5 mol% the diameter increased to 38 nm. The small dependence of particle diameter on the concentration of OEP-Co-4OA was not observed before for the OEP-Cu loaded LNP [24] . At high concentrations of OEP-Co-4OA (10 mol%) neither the particle size of LNP nor the P.I. were increased. For the free OEP-Co-4OA nanocrystal though, when measured just in buffer, their diameter was 77 nm. Thus, the size results and the low P.I. measured at high OEP-Co-4OA concentrations would suggest a good encapsulation of the complex inside LNP of up to at least 10 mol%. Thus, for the final particle, Scheme 2 of the OEP-Co-OA loaded NPs shows the critical dimensions of the components of the LNP, i.e., the TO core and the lipid monolayer. The addition of 4OA to the formulation did not result in a significant increase in the diameter of the NPs (31 nm to 40 nm at a confidence of P < 0.05) but did ensure chelation and retention of the cobalt. From x-ray diffraction it is known that the thickness of a DSPC bilayer in its liquid phase is 4.2 nm [77] and that Cholesterol increases PC bilayer thicknesses by a factor of 1.2 to 5 nm [78] . Thus, the lipid monolayer has a thickness of 2.5 nm and PEG 2000 extends 3.5 nm [63] from the bilayer surface. This gives a total diameter for the OEP-Co-4OA LNP of 40 nm, and the hydrophobic core represents 28 nm in diameter.
Encapsulation efficiency of cobalt in the final LNP
When measured by fluorescent spectroscopy, the maximum OEP-Co-4OA loading inside the final LNP was actually found to be 5 mol% (Fig. 6B) . This value is consistent with our previous work where we measured a similar encapsulation efficiency of OEP and OEP-Cu inside the same LNP [24] . Here the fluorescence intensity gradually increased with increasing concentration of OEP-Co-4OA until a plateau was reached at 5 mol% concentration. Thus, if any concentration of OEP-Co-4OA above 5 mol% was in excess it was excluded from the LNPs and likely present as 77 nm nanocrystals. 57 
Retention of
Co in PBS and stability of the final LNPs against aggregation
Once incorporated, the labelling stability of LNP loaded with OEPCo-4OA was evaluated upon incubation in PBS and human serum at 37°C for 24 h, which was the time frame needed for the encapsulated 57 Co to inform tumor accumulation in the in vivo studies. From our previous results with OEP-Cu [24] , the OEP-Cu complex was shown to be well-retained in the liquid core of LNP made of TO. It was therefore expected that the OEP-Co-4OA would also be well retained inside the LNP suspended in PBS and serum. Results shown in Fig. 7A confirmed this and demonstrated the high retention of 57 Co in LNP when the radionuclide was chelated in the hexacoordinate OEP-57 Co-4OA complex. In contrast, when OA was not included in the formulation, cobalt was released from the planar tetra-coordinate OEP-57 Co, i.e., the cobalt retention half-life in the absence of OA from OEP- 57 Co was only 22 h. While not shown on the plot in Fig. 7A (time axis only up to 24 h) the half-life of 57 Co retention in OEP-57 Co-OA was measured to be 7 days. This result clearly proved the important role of OA to complete the preferential hexa-coordination number of cobalt in order to stabilize the ion in the chelate and LNP. While other water-soluble chelators for cobalt, such as DOTA [35, 79] or NOTA [38] can provide 6 electron donor pairs to form the stable octahedral chelate with cobalt, these chelators are too hydrophilic to be well-retained in the TO core. Also, the size measurements for LNP labelled with OEP-Co and OEPCo-4OA shown in Fig. 7B demonstrated good in vitro stability for both LNP and showed that they are stabilized against aggregation in salt solutions and might therefore be expected to remain as individual NPs in the blood stream and so capable of crossing the leaky endothelial barrier into the tumor interstitium via the EPR effect. 57 Co-OA Finally, the biodistribution study was carried out for LNP labelled with OEP- 57 Co-4OA (from now identified as simply 57 Co-LNP). The concept was that the small NPs would be likely to follow the well-established extravasation and uptake of LDLs by tumors [80, 81] and so allow the diagnostic particle to extravasate into the tumor interstititum by the EPR effect [6, [82] [83] [84] . The results in Fig. 8 show the biodistribution profile of the 57 Co-LNP at 1, 4 and 24 h after injection.
Biodistribution study of LNP loaded with OEP-
LNP in blood: circulation half-life and renal excretion
The results from Fig. 7A showed 96% of the 57 Co was well-retained in the 57 Co-LNP in PBS buffer and 94% in serum at 4 h, and so, if we assume that these data hold in vivo, then to a first approximation we can essentially quantify the concentration of 57 Co-LNP in blood by measuring the concentration of 57 Co. As shown in Fig. 8 , after an injected dose of 4.3 × 10 1157 Co-LNP (injected i.v. at a concentration of 300 μM and radioactivity of 62 ± 4 kBq per animal) the concentration of 57 Co-LNP in the blood decreased with time from 33% ID/g at 1 h, to 27% ID/ g at 4 h, and down to 4% ID/g at 24 h after injection. This data can then be simply plotted with respect to time to provide half-lives for blood circulation and the tumor uptake rate. Fig. 9 shows the data plotted on a linear time scale and the measured data point are fitted to a first order exponential with respect to time. The blood circulation concentrations of the 57 Co-LNP gave an estimated half-life of 7.2 h. While the half-life was calculated based on just three time points, even from this limited data set, it can be seen that, the estimated halflife of 57 Co-LNP of 7.2 h is only slightly shorter than other recently made and tested PET imageable NPs. These include: similarly sized (20.6 ± 5.2 nm), negatively charged zeta potential (−6.07 ± 0.71 mV) PEGylation-free biomimetic porphyrin nanoplatform,(t 1/2 9 h) [47] ; and the larger diameter, 64 Cu-DOTA-containing liposomes (t 1/2 10 h, 96.1 ± 0.8 nm diameter, zeta potential −3.8 ± 0.9 mV) [85] . It is therefore encouraging that there is sufficient circulation halflife in the blood stream to see good accumulation in the tumor for these sized LNP.
When compared with molecular imaging agents, such as the somatostatin receptor targeted peptide labelled with 57 Co ( 57 Co-DOTATATE) in the same AR42J tumor model [35] , 57 Co-LNP showed longer circulation times in the blood. As expected and desired for a molecular contrast agent, 57 Co-DOTATATE was already onlỹ 0.9% ID/g 1 h after administration and was totally cleared from the blood stream at 24 h. Hence, as it was designed to do, 57 Co-DOTATATE gave very little background signal even at 1 h. In contrast, as required by the formulation, the chelated retention and PEGylation maintained a significant amount of the 57 Co-LNP in the blood stream over a significant 24 h time period.
LNP has a particle size of 40 nm that is expected to be large enough The average particle size of the 57 Co-LNP was 40 nm.
to avoid renal clearance (> 5 nm). In fact, we observed a maximum accumulation in the kidneys of only 5%ID/g, which could easily reflect the non-perfused blood volume of this highly vascularized organ. Interestingly our value of 5%ID/g is similar to the values obtained for porphyrin-loaded nanoparticles reported by others [47] , with 20 nm diameter. This value is however much lower than the value obtained for the molecular imaging agent 57 Co-DOTATATE (15%ID/g) [35] , that is mainly eliminated through the kidneys, so we can conclude that the LNP are not being eliminated from circulation through the kidney but through the liver, as discussed next.
LNP accumulation in the liver
One of the most effective ways the body uses to remove foreign NPs (even beneficial ones) from the blood stream is via opsonization by blood borne clotting agents and recognition of the opsonized NP by the Kupffer cells of the liver [67] . Fig. 8 shows that the liver accumulation of our PEGylated 57 Co-LNP 24 h after injection was 23%ID/g. For comparison, this was similar to the liver uptake values reported by Cui et al., for their non-PEGylated, porphyrin-based ultra-small nanostructures termed porphylipoprotein (PLP) with a diameter of 20 nm [47] .
LNP accumulation in tumors
Finally, as mentioned above, the most important result is that the NPs could indeed accumulate in tumors up to levels that are similar to many of the NPs used recently [5] . Comparing to specific NPs tested in the same AR42J tumor model by others, Helbok et reported
111
In liposomes targeted with the somatostatin analogue tyrosine-3-octreotide as a tumor targeting agent [86] . NP biodistribution studies showed that only moderate tumor uptake was found in the xenografted nude mice (< 2.5% ID/g) at 4 h post injection, compared to 6% ID/g for the 57 CoLNPs (see Fig. 9 ). The 57 Co-LNP tumor uptake was also much higher than for poly-lactate polymeric micelles with a much larger 100 nm diameter (2%ID/g) again in the same tumor model of pancreatic cancer [87] .
For comparison with a molecular imaging agent, the tumor uptake of 57 Co-LNP was, as expected, very different to 57 Co-DOTATATE. The 57 Co-LNP tumor uptake was only at about half the values reported for the somatostatin-targeted molecular agent 57 Co-DOTATATE [35] . As shown in Fig. 8 , and replotted in Fig. 9 , tumor accumulation of 57 Co-LNP increased over time, from 3%ID/g to 6%ID/g to 9.4%ID/g measured at 1 h, 4 h, and 24 h respectively after injection. Thus, compared to 57 Co-DOTATATE, while the tumor accumulation of 57 Co-LNP was lower than the accumulation of 57 Co-DOTATATE that shows a maximum accumulation of 24%ID/g [35] , 57 Co-LNP tumor accumulation was nevertheless, almost 50% of this molecular agent's accumulation. We calculated a tumor-to-blood ratio of 1.6 ( Fig. S2) for 57 Co-LNP 24 h after injection. This value is much lower (by a factor of [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] than the values preferred and obtained for small peptides targeted to the somatostatin receptor (tumor-to-blood ratio of 121-137) [35] . This is because small molecules can extravasate into the tumor interstitium due to its small size (a few nanometers) and active targeting, resulting in a fast and high tumor accumulation and penetration of 24%ID/g 1 h after injection and a rapid and complete loss from the blood stream. The important point here is that, the LNPs were not designed to be used as a tumor-diagnostic agent in the classical sense of simply detecting metastatic tumors. Rather, they were designed to be used in the context of an individualized medicine strategy (see below, "PET imaging in personalized nanomedicine"), in diagnosis and therapy using NPs that need to accumulate in the tumor interstitium. Thus, as is now clear from the biodistribution study, NPs with a defined diameter (40 nm) and surface properties (PEGylation) can accumulate at the tumor site. Information of tumor accumulation provided by the LNP can now be used to predict the expected pharmacokinetics of therapeutic NPs with the same diameter and coating composition, but now carrying a core of pure drug. Their ability to accumulate in tumors would be an essential event that would determine their potential for efficacy. As we have seen, when compared with molecular imaging agents, despite the longer circulation time and the smaller tumor uptake for the LNPs, tumor-uptake was still twice that for other LDL-sized NPs [47] or liposomes [85] , albeit in different tumor models. That is, since our LNPs were designed to accumulate in the perivascular space of metastatic tumors, a half-life of 7.2 h might well be long enough to achieve the overall goal of measuring tumor permeability and to signify that sufficient NP drug could be subsequently accumulated to expect efficacy.
LNP Pharmacokinetic vs pure cobalt
One criticism could be the absence of a free cobalt control. To this we point out that our in vitro data (Fig. 7 . Co retention and LNP size stability in PBS at 37°C) showed how well cobalt was retained in the specifically chelated Co-OEP-OA in the nanoparticle. Mainly because of this data we did not do a pure cobalt chloride control in this first study of the nanoparticles. Also, data in vivo in the literature for pure cobalt suggests that all our measurements did in fact reflect the behavior of the nanoparticle-encapsulated cobalt because the half-lives for its blood circulation and for liver retention are vastly different compared to those reported for pure cobalt.
For example, in Jansen's 1996 paper [7] , after intravenous administration in rats, all tissues showed rapid 55 Co uptake, but the liver and bladder accumulated most of the 55 Co. In our studies we did not report the bladder content, and there is certainly a strong Cobalt-signal in the liver. However, in Jansen's study the biological half-life of free cobalt was 25.5 h, and the residence half-life in the liver was 7.5 h. This is in sharp contrast to our study of the cobalt-retained nanoparticles where the circulation half-life of the cobalt signal was only 7.5 h and accumulation in the liver was still increasing at 24 h (see Fig. 8 . Biodistribution of LNP labelled with OEP- 57 Co-4OA in mice 1, 4, and 24 h).
Thus, given these vastly different pharmacokinetics for free Cobalt versus our well-encapsulated, chelated cobalt, we can conclude that it is indeed the intact nanoparticles that still retain their trapped Cobalt and not free cobalt that is giving any of these signals. It is the nanoparticleencaspulated cobalt that is reporting nanoparticle-accumulation in the tumor.
PET imaging and Individualized anti-cancer nanomedicine
Ongoing studies in our lab and collaborators are focused on endogenous-inspired NP designs for metastatic cancer, including: synthesis, characterization, and formulation of a pro-drug Niclosamide Stearate (NSNP) for i.v. injection [71] ; NSNP testing for in vitro celluptake and cytotoxicity in glioblastoma, breast & prostate cancers. These prodrug nanoparticles are showing promising and positive results in in vivo preclinical studies in a flank and metastatic tumors with growth delays and extended lifetimes for the NSNP-treated animals. However, it is essential that the EPR effect is proven and characterized in order for the therapeutics to have any chance of success. Thus, as laid out in this paper, any clinical (or preclinical) testing and use of the nanoparticle design can now include PET-imageable nanoparticles which in combination with the NSNPs forms a suite of diagnostic and therapeutic "Individualized nanomedicines" for cancer.
Measurement of the tumor accumulation of nanomedicines to predict the anti-cancer therapy is recognized as a key step in the development of "Individualized-" or "personalized-nanomedicines" [24, 88, 89] , and that is exactly what the purely diagnostic LNPs presented here can offer. The overall concept was to provide a diagnostic (PET-imageable) and therapeutic (hydrophobic drugs [4, 71] option in two separate NPs that have different content, but are physically similar in terms of surface chemistry to enhance circulation half-life (a sterically stabilizing PEG layer) and size to promote vascular extravasation and tumor accumulation (20-40 nm diameter). It is envisioned that a "personalized anti-cancer nanomedicine approach" relies on the selection of patients who are the more likely responders to a particular nanomedicine treatment. Using the fatty acid synthase inhibitor Orlistat [90] as an example, it would:
1. detect the presence of the tumors (e.g., by 18 FDG) 2. determine by an additional functional imaging agent that the tumor was susceptible to a certain drug-target pathway (e.g., 11 C-acetate signifying activity of fatty acid synthase), 3. quantitatively evaluate NP access to, and accumulation in, the tumor interstitium [88] , by for example, a PET-imageable LNP, 4. administer the drug NP for therapy. (i.e. Orlistat nanoparticles to block the fatty acid synthase pathway).
Thus, these imageable NPs would necessarily be of the same size and physical state as the subsequent drug NP. Tumor accumulation of NPs has been quantitatively measured in preclinical studies by PET [44, [91] [92] [93] and in human patients by SPECT [9] imaging using NPs labelled with long-lived radionuclides. What has been achieved now is a method to prepare NPs with the same size and structure as the subsequent LDL-sized therapeutic nano-medicines, labelled in their hydrophobic core with a long-lived PET radionuclide that, again, physicochemically (mainly size and surface) resembles the subsequent drug NP that would provide the therapeutic intervention.
Conclusions
The additional hydrophobic chelator OA was indeed needed to obtain a stable octahedral OEP-Co-4OA. After 24 h in vitro incubation, 57 Co was actually well-retained at levels of 89% inside LNP in the OEP- 57 Co-4OA complex, compared to the OEP- 57 Co complex (38%), which is important for in vivo administration and to ensure a sufficient blood circulatory half-life. The half-life of the retention in OEP- 57 Co-OA was 7 days, while in OEP- 57 Co it was only 22 h. Because of this high retention, we could measure the circulation half-life and organ and tissue biodistribution of 40 nm diameter LNPs containing 57 Co, including the appearance of tumor accumulation in vivo. Thus, the LNP containing the OEP-Co-4OA complex, with diameters of 40 nm, accumulated in pancreatic AR42J tumors of mice at concentrations of 9.4% ID/g. The method described in the present work for the core-labelling of LNPs with cobalt is now ready for labeling of NPs with 55 Co, or indeed other hexadentate radionuclides of interest (including, 89 Zr, 86 Y and the Auger-emitter 58m Co) for preclinical in vivo PET-imaging and radiotherapeutics.
